Cao Shaocong, Peng Tao
Shenzhen Hospital of Guangzhou University of Chinese Medicine, Shenzhen, China.
Case Rep Oncol. 2024 Nov 19;17(1):1322-1326. doi: 10.1159/000542103. eCollection 2024 Jan-Dec.
The incidence of chemotherapy-induced rhabdomyolysis is rare, but it is a syndrome that may cause death and should be paid attention to clinically.
Here, we report a case of rhabdomyolysis in an ovarian cancer patient after chemotherapy. After the symptoms were relieved, the chemotherapy regimen was changed, and rhabdomyolysis occurred again.
The occurrence of rhabdomyolysis is mainly caused by certain specific chemotherapy drugs such as gemcitabine and paclitaxel and is not closely related to other factors such as the patient's constitution or genetic factors. And the occurrence of rhabdomyolysis can be caused by conventional doses of drugs rather than high dose. If rhabdomyolysis occurs and is completely relieved, chemotherapy may be considered again depending on the patient's condition and physical condition. However, caution should be exercised in selecting drugs to avoid recurrence of rhabdomyolysis, and the condition should be closely monitored.
化疗诱导的横纹肌溶解症发病率很低，但它是一种可能导致死亡的综合征，临床上应予以关注。
在此，我们报告1例卵巢癌患者化疗后发生横纹肌溶解症的病例。症状缓解后更改了化疗方案，横纹肌溶解症再次发生。
横纹肌溶解症的发生主要由某些特定化疗药物如吉西他滨和紫杉醇引起，与患者体质或遗传因素等其他因素无密切关系。而且常规剂量而非高剂量药物即可导致横纹肌溶解症的发生。如果发生横纹肌溶解症且完全缓解，可根据患者病情和身体状况考虑再次进行化疗。然而，选择药物时应谨慎，以避免横纹肌溶解症复发，并应密切监测病情。
